Pegbelfermin (PGBF): As a polyethylene glycol‐conjugated analog of FGF21 with an extended half‐life that enables weekly dosing, pegbelfermin was found to present better NAFLD activity scores, liver stiffness (magnetic resonance elastography) and steatosis (magnetic resonance imaging‐proton density fat fraction) improvements than the placebo control in a randomized phase II trial (NCT03486912).[539] In consistency, PGBF was found to improve hepatic fibrosis and liver injury/inflammation in patients with NASH and stage I‐III fibrosis in another phase II trial (NCT02413372).[540]. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatotic liver disease.